BNB PLUS CORP (BNBX)
NASDAQFinancialsBiotechnologySnapshot 2026-11-05
$0.14-12.50%
Close 2026-08-10 · 1-day change
NASDAQFinancialsBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · BNBX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.7% |
| Our one-year growth estimate | diamond | -43.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 41.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
BNBX — officer change
Dated 2026-09-03
Director — Robert B. Catell, Joseph D. Ceccoli, Dr. Yacov Shamash, Richard Shorten, Todd Larsen, Lok Lee: Three directors resigned and were immediately replaced by new appointees, including a strategic advisor with significant affiliations to a major shareholder, indicating a board reshuffle rather than a loss of senior executive management.
Why it matters: BNBX reported a $3.24 million operating loss in 2026-Q3 while starting its new plan. Smaller losses would show better cost control; larger losses would raise execution concerns.
Watch forA quarter showed an operating loss under $3.24 million.
Also watch forA reported quarter shows an operating loss of $3.24 million or more.
Why it matters: BNBX has shifted from holding digital assets to building infrastructure. A signed deal would show that the new plan is moving into practice.
Supportive ifBNBX announces a signed deal with a named customer, partner, or infrastructure provider. The deal lists services and clear terms.
Worry ifBNBX reports no signed infrastructure deal in its next update, or says the plan is delayed or changed.
Why it matters: BNBX moved to OTCQB after failing Nasdaq's $1.00 minimum bid rule. A ruling will show whether Nasdaq trading can resume.
Watch forThe Listing Council reverses or changes the delisting ruling. BNBX announces a path back to Nasdaq.
Also watch forThe Listing Council upholds the ruling, or BNBX says Nasdaq trading will not resume.
Why it matters: Reported revenue fell from $1.02 million in 2026-Q2 to $605,000 in 2026-Q3. A rebound would support the case that LineaRx can help fund the shift.
Watch forA quarter showed revenue above $1.02 million. LineaRx still made a profit.
Also watch forA reported quarter shows revenue at or below $605,000, or LineaRx reports a loss.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$384 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,397 loss on $10,000 · 14.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,857 loss on $10,000 · 98.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: BNBX says it wants to unlock value from LineaRx. A completed deal would show whether the unit can bring in cash or support a partner's work.
Supportive ifBNBX announces a signed LineaRx sale, license, or partnership and states the key terms.
Worry ifBNBX reports no LineaRx deal and gives no new steps or timing for monetizing the unit.